FNY Partners Fund’s Nektar Therapeutics NKTR Stock Holding History

FNY Partners Fund’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-67	Closed	-$12	–	1497
2016 Q4	$12	Buy	+67	New	+$13.6K	﹤0.01%	414

Other funds holding NKTR

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bridger Management New York $128M AUM 9.54% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

FNY Partners Fund's NKTR Position: Q1 2017 in Review

FNY Partners Fund sold out of Nektar Therapeutics (NKTR) in Q1 2017, closing a stake of 67 shares — an estimated $12 sold.

FNY Partners Fund first reported a position in NKTR in Q4 2016 and held it in 1 quarter. The position peaked at $12 in Q4 2016. 201 funds tracked by Wall St. Rank hold NKTR as of Q1 2017.

FNY Partners Fund reported no remaining Nektar Therapeutics position as of Q1 2017 after selling out during the quarter.
FNY Partners Fund sold 67 Nektar Therapeutics shares in Q1 2017, an estimated $12.
FNY Partners Fund first reported a position in Nektar Therapeutics in Q4 2016 and held it in 1 quarter.
FNY Partners Fund's Nektar Therapeutics position peaked at $12 in Q4 2016.
201 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2017.

Based on FNY Partners Fund's 13F filing for Q1 2017, filed 15 May 2017.